Aardvark Therapeutics Investors Face October Deadline in Fraud Suit

The litigation centers on allegations that Aardvark Therapeutics and its executives issued a registration statement and subsequent public disclosures containing materially false information. According to the complaint, the company failed to disclose that its drug candidate, ARD-101, possessed a safety profile inferior to what was presented to shareholders. Consequently, the lawsuit argues that the firm overstated the clinical, regulatory, and commercial viability of the drug, leading to financial losses for investors when the actual details of the drug's performance emerged.

Investors wishing to participate in the class action are not required to serve as lead plaintiff to be eligible for potential recovery. Those interested in assuming a leadership role must file a motion with the court before the October deadline. Retaining specific counsel is a choice for individual investors, as no class has been certified at this stage. The Rosen Law Firm, which is soliciting participants for the suit, notes that the case is being pursued on a contingency fee basis, meaning investors do not incur out-of-pocket costs for legal representation.